Immunohistochemical detection of p53 and MDM2 expressions in liposarcoma with World health organization classification
dc.contributor.author | Arıcı, Akgül | |
dc.contributor.author | Özgür, Tümay | |
dc.contributor.buuauthor | Uǧraş, Nesrin | |
dc.contributor.buuauthor | Yalçınkaya, Ulviye | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAH-8924-2021 | tr_TR |
dc.contributor.researcherid | AAH-2716-2021 | tr_TR |
dc.contributor.scopusid | 55386535600 | tr_TR |
dc.contributor.scopusid | 6508300295 | tr_TR |
dc.date.accessioned | 2023-05-12T11:27:30Z | |
dc.date.available | 2023-05-12T11:27:30Z | |
dc.date.issued | 2013 | |
dc.description.abstract | Background: Liposarcomas are among the most common soft tissue sarcomas in adulthood. Aim: The purpose of the study is to perform a histopathologic typing according to World Health Organization (WHO) classification of cases diagnosed with liposarcoma and to examine the difference of p53 and MDM2 expressions. Materials and Methods: The haematoxylin-eosin stained sections of 48 subjects enrolled in the study have been evaluated on the basis of the WHO classification for liposarcoma and sections stained using p53 and MDM2. Statistical Analysis Used: Chi-Square test was applied. Results: 20 subjects were diagnosed with well-differentiated liposarcoma (WLS), 16 myxoid liposarcoma (ML), 7 pleomorphic liposarcoma (PL), and 5 de-differentiated liposarcoma (DLS). The number of cases stained positive with MDM2 and p53 were positive correlated in all subjects (P = 0.02). p53 and MDM2 positivity increased in high grade tumors (P = 0.01). Conclusion: p53 and MDM2 immuno-reactivity was found to be potentially useful in liposarcoma diagnosis but a definitive implication would be rather unhealthy due to the small number of cases in our study. | en_US |
dc.identifier.citation | Arıcı, A. (2013). “Immunohistochemical detection of p53 and MDM2 expressions in liposarcoma with World health organization classification”. Indian Journal of Cancer, 50(3), 164-169. | en_US |
dc.identifier.endpage | 169 | tr_TR |
dc.identifier.issn | 0019-509X | |
dc.identifier.issn | 1998-4774 | |
dc.identifier.issue | 3 | tr_TR |
dc.identifier.pubmed | 24061453 | tr_TR |
dc.identifier.scopus | 2-s2.0-84885404443 | tr_TR |
dc.identifier.startpage | 164 | tr_TR |
dc.identifier.uri | https://doi.org/10.4103/0019-509X.118717 | |
dc.identifier.uri | http://hdl.handle.net/11452/32647 | |
dc.identifier.volume | 50 | tr_TR |
dc.identifier.wos | 000339909300002 | |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wolters Kluwer Medknow Publications | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Indian Journal of Cancer | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Oncology | en_US |
dc.subject | Liposarcoma | en_US |
dc.subject | MDM2 | en_US |
dc.subject | p53 | en_US |
dc.subject | World health organization classification | en_US |
dc.subject | Gene amplification | en_US |
dc.subject | Cell liposarcoma | en_US |
dc.subject | Tumors | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Patterns | en_US |
dc.subject.emtree | Eosin | en_US |
dc.subject.emtree | Hematoxylin | en_US |
dc.subject.emtree | Protein MDM2 | en_US |
dc.subject.emtree | Protein p53 | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cancer classification | en_US |
dc.subject.emtree | Cancer localization | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Histopathology | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human tissue | en_US |
dc.subject.emtree | Immunohistochemistry | en_US |
dc.subject.emtree | Immunoreactivity | en_US |
dc.subject.emtree | Liposarcoma | en_US |
dc.subject.emtree | Myxosarcoma | en_US |
dc.subject.emtree | Pleomorphic liposarcoma | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Well differentiated liposarcoma | en_US |
dc.subject.emtree | World health organization | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunohistochemistry | en_US |
dc.subject.mesh | Liposarcoma | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Proto-oncogene proteins c-mdm2 | en_US |
dc.subject.mesh | Soft tissue neoplasms | en_US |
dc.subject.mesh | Tumor markers, biological | en_US |
dc.subject.mesh | Tumor suppressor protein p53 | en_US |
dc.subject.mesh | World health organization | en_US |
dc.subject.scopus | Liposarcoma; Spermatic Cord; Case Report | en_US |
dc.subject.wos | Oncology | en_US |
dc.title | Immunohistochemical detection of p53 and MDM2 expressions in liposarcoma with World health organization classification | en_US |
dc.type | Article | |
dc.wos.quartile | Q4 | en_US |